Sandi See Tai Biography and Net Worth

Insider of Lexeo Therapeutics

Sandi See Tai, MD has been promoted to Chief Development Officer. Dr. See Tai previously served as Vice President and Development Head for Rare Disease at Pfizer, where she led clinical programs in Rare Cardiovascular, Neurology, Renal, and Pulmonary diseases. During her time at Pfizer, she successfully led the late-stage clinical development of tafamidis for ATTR cardiomyopathy, achieving global regulatory approvals. Dr. See Tai brings nearly 20 years of pharmaceutical industry experience to Lexeo, including roles at Wyeth Pharmaceuticals and academic experience as an Assistant Professor of Pediatrics at Drexel University College of Medicine.

What is Sandi See Tai's net worth?: The estimated net worth of Sandi See Tai is at least $411.84 thousand as of November 18th, 2025. Ms. See Tai owns 65,476 shares of Lexeo Therapeutics stock worth more than $411,844 as of April 21st. This net worth approximation does not reflect any other investments that Ms. See Tai may own. Learn More about Sandi See Tai's net worth.
How do I contact Sandi See Tai?: The corporate mailing address for Ms. See Tai and other Lexeo Therapeutics executives is 345 Park Avenue South, 6th Floor, New York, NY 10010, United States. Lexeo Therapeutics can also be reached via phone at 212-547-9879 and via email at [email protected]. Learn More on Sandi See Tai's contact information.
Has Sandi See Tai been buying or selling shares of Lexeo Therapeutics?: Sandi See Tai has not been actively trading shares of Lexeo Therapeutics during the last ninety days. Most recently, Tai Sandi See sold 386 shares of the business's stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $9.27, for a transaction totalling $3,578.22. Following the completion of the sale, the insider now directly owns 65,476 shares of the company's stock, valued at $606,962.52. Learn More on Sandi See Tai's trading history.
Who are Lexeo Therapeutics' active insiders?: Lexeo Therapeutics' insider roster includes Sandi See Tai (Insider), and Richard Townsend (CEO). Learn More on Lexeo Therapeutics' active insiders.
Are insiders buying or selling shares of Lexeo Therapeutics?: In the last twelve months, insiders at the sold shares 18 times. They sold a total of 102,155 shares worth more than $661,185.22. The most recent insider tranaction occured on April, 6th when CEO Richard Nolan Townsend sold 55,000 shares worth more than $312,950.00. Insiders at Lexeo Therapeutics own 5.3% of the company. Learn More about insider trades at Lexeo Therapeutics.
Information on this page was last updated on 4/6/2026.

Sandi See Tai Insider Trading History at Lexeo Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/18/2025	Sell	386	$9.27	$3,578.22	65,476
10/17/2025	Sell	3,888	$8.94	$34,758.72	65,862
8/18/2025	Sell	382	$4.67	$1,783.94	58,860
5/16/2025	Sell	367	$2.77	$1,016.59	59,242
2/19/2025	Sell	1,486	$4.41	$6,553.26	53,889

Sandi See Tai Buying and Selling Activity at Lexeo Therapeutics

Lexeo Therapeutics Company Overview

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Today's Range

Now: $6.29

$6.22

$6.63

50 Day Range

MA: $6.36

$5.27

$7.44

2 Week Range

Now: $6.29

$2.43

$10.99

Volume

763,765 shs

Average Volume

1,022,092 shs

Market Capitalization

$466.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99